No role for the CYP3A5*3 polymorphism in intestinal and hepatic metabolism of midazolam

被引：0
|
作者：
D. Tomalik-Scharte
O. Doroshyenko
J. Kirchheiner
A. Jetter
A. Lazar
T. Klaassen
D. Frank
C. Wyen
G. Fätkenheuer
U. Fuhr
机构：
[1] University of Cologne,Department of Pharmacology, Clinical Pharmacology
[2] University of Ulm,Department of Pharmacology of Natural Products and Clinical Pharmacology
[3] University Hospital Zürich,Division of Clinical Pharmacology and Toxicology, Department of Internal Medicine
[4] University of Cologne,Department I of Internal Medicine, University Hospital
来源：
European Journal of Clinical Pharmacology | 2008年 / 64卷
关键词：
Midazolam; Alfentanil; CYP3A Activity; CYP3A5 Expression; CYP3A5 Substrate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1033 / 1035
页数：2
相关论文
共 50 条
  • [1] No role for the CYP3A5*3 polymorphism in intestinal and hepatic metabolism of midazolam
    Tomalik-Scharte, D.
    Doroshyenko, O.
    Kirchheiner, J.
    Jetter, A.
    Lazar, A.
    Klaassen, T.
    Frank, D.
    Wyen, C.
    Faetkenheuer, G.
    Fuhr, U.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 64 (10) : 1033 - 1035
  • [2] No effect of CYP3A5 polymorphism on intestinal or hepatic metabolism of midazolam
    Tomalik-Scharte, D
    Doroshyenko, O
    Kirchheiner, J
    Jetter, A
    Lazar, A
    Klaassen, T
    Frank, D
    Fuhr, U
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 61 (09) : 721 - 721
  • [3] Does CYP3A5 polymorphism influence everolimus intestinal and hepatic metabolism?
    Rouguieg-Malki, K.
    Picard, N.
    Marquet, P.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2010, 24 : 72 - 72
  • [4] Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism
    Lin, YS
    Dowling, ALS
    Quigley, SD
    Farin, FM
    Zhang, J
    Lamba, J
    Schuetz, EG
    Thummel, KE
    MOLECULAR PHARMACOLOGY, 2002, 62 (01) : 162 - 172
  • [5] The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism
    McGraw, Joseph
    Cherney, Mitchell
    Bichler, Katherine
    Gerhardt, Armin
    Nauman, Mirielle
    TOXICOLOGY LETTERS, 2019, 315 : 9 - 13
  • [6] Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics
    Fröhlich, M
    Hoffmann, MM
    Burhenne, J
    Mikus, G
    Weiss, J
    Haefeli, WE
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 58 (04) : 443 - 444
  • [7] The genetic determinants of the CYP3A5 polymorphism
    Hustert, E
    Haberl, M
    Burk, O
    Wolbold, R
    He, YQ
    Klein, K
    Nuessler, AC
    Neuhaus, P
    Klattig, J
    Eiselt, R
    Koch, I
    Zibat, A
    Brockmöller, J
    Halpert, JR
    Zanger, UM
    Wojnowski, L
    PHARMACOGENETICS, 2001, 11 (09): : 773 - 779
  • [8] CYP3A5 polymorphism, amlodipine and hypertension
    Y-P Zhang
    X-C Zuo
    Z-J Huang
    J-J Cai
    J Wen
    D D Duan
    H Yuan
    Journal of Human Hypertension, 2014, 28 : 145 - 149
  • [9] CYP3A5 polymorphism, amlodipine and hypertension
    Zhang, Y-P
    Zuo, X-C
    Huang, Z-J
    Cai, J-J
    Wen, J.
    Duan, D. D.
    Yuan, H.
    JOURNAL OF HUMAN HYPERTENSION, 2014, 28 (03) : 145 - 149
  • [10] CYP3A5 genotypes and effect of verapamil on midazolam pharmacokinetics
    Wang, YH
    Jin, Y
    Hu, ZQ
    Ho, H
    Hamman, MA
    Gorski, JC
    Hall, SD
    DRUG METABOLISM REVIEWS, 2004, 36 : 119 - 119
12345